Cisplatin-based chemotherapy remains the standard care for NSCLC patients, but many patients are prone to develop drug resistance after cisplatin treatment.24 It has been reported that many RNAs and proteins participate in modulating cisplatin resistance in NSCLC patients.25,26 Recently, Li et al. have demonstrated that PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer.10 In this study, through constructing drug-resistant cell lines (A549/DDP and PC-9/DDP), we found that PROM2 reduced cisplatin sensitivity in lung cancer cells. This evidence concerns the gene PROM2 and non-small cell lung carcinoma.